SCHEMBL4746387

SCHEMBL4746387

Cc1ccc2c(c1)c(-c1ccc3ccc(-c4cc5c6ccc(C)c7c6c(cc5c5ccc(C)cc45)-c4ncccc4-7)cc3c1)cc1c3ccc(C)c4c3c(cc21)-c1ncccc1-4

nearest known ligand 0.33

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 1/20 0.33
ALDH1A1 P00352 3/20 0.33
TGFBR1 P36897 5/20 0.32
CCR1 P32246 1/20 0.31
CCR5 P51681 1/20 0.31
CCR8 P51685 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
BCHE P06276 1/20 0.31
CTSD P07339 1/20 0.30
BACE1 P56817 1/20 0.30
HSD11B1 P28845 1/20 0.30
KDM4E B2RXH2 1/20 0.30
LMNA P02545 1/20 0.30
GAA P10253 1/20 0.30
HPGD P15428 1/20 0.30
HSD17B10 Q99714 1/20 0.30
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4746389 0.97 DHODH (0.34) DHODHALDH1A1TGFBR1CCR1CCR5
SCHEMBL4745812 0.96 ALDH1A1 (0.34) DHODHALDH1A1CCR1CCR5CCR8
SCHEMBL4746339 0.92 DHODH (0.36) DHODHALDH1A1TGFBR1BCHEKDM4E
SCHEMBL4746063 0.92 PIK3CD (0.38) ALDH1A1KDM4ELMNANPC1RAB9A
SCHEMBL4746317 0.91 DHODH (0.35) DHODHALDH1A1BCHEKDM4ELMNA
SCHEMBL4746018 0.91 ALDH1A1 (0.44) DHODHALDH1A1TGFBR1BACE1KDM4E
SCHEMBL4746019 0.91 ALDH1A1 (0.44) DHODHALDH1A1TGFBR1CCR1CCR5
SCHEMBL4746099 0.90 ABL1 (0.36) ALDH1A1KDM4E
SCHEMBL4746310 0.90 BCHE (0.34) DHODHALDH1A1TGFBR1BCHEKDM4E
SCHEMBL4746312 0.88 BCHE (0.34) DHODHALDH1A1TGFBR1BCHEKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173275-B2 Azaindenochrysene derivative and organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2012-05-08 US disclosed
US-8173275-B2 Azaindenochrysene derivative and organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2012-05-08 US disclosed
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2010-05-13 US disclosed
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE NR2E3, OR51E2, AZI2 DHODH 18/4885ALDH1A1 179/4885TGFBR1 1895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.